Literature DB >> 16099041

Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia.

Joli R Weiss1, Julie A Baker, Maria R Baer, Ravi J Menezes, Susan Nowell, Kirsten B Moysich.   

Abstract

Regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of hematologic cancer, although previous results have been inconsistent. The current study investigated the effects of aspirin or acetaminophen use on adult acute leukemia risk among 169 individuals with leukemia and 676 age and sex matched hospital controls with non-neoplastic conditions who completed a comprehensive epidemiologic questionnaire. Results indicate that regular aspirin use may be associated with a modest decrease in leukemia risk [adjusted odds ratio (aOR), 0.84; 95% confidence interval (CI), 0.59-1.21]. In contrast, ever using acetaminophen was associated with elevated leukemia risk (aOR, 1.53; 95% CI, 1.03-2.26). Results did not differ between men and women. Other studies have demonstrated that acetaminophen is associated with transient decreases in DNA repair, and lymphocytes may be particularly susceptible to DNA damage, suggesting a mechanism for the elevated acute leukemia risk observed among acetaminophen users.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16099041     DOI: 10.1016/j.leukres.2005.06.023

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2.

Authors:  C Pepper; J G Mahdi; A G S Buggins; S Hewamana; E Walsby; E Mahdi; A Al-Haza'a; A J Mahdi; T T Lin; L Pearce; L Morgan; I D Bowen; P Brennan; C Fegan
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

2.  Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia.

Authors:  Julie A Ross; Cindy K Blair; James R Cerhan; John T Soler; Betsy A Hirsch; Michelle A Roesler; Rodney R Higgins; Phuong L Nguyen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-29       Impact factor: 4.254

3.  Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study.

Authors:  Roland B Walter; Filippo Milano; Theodore M Brasky; Emily White
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 4.  Can Aspirin and Cancer Prevention be Ageless Companions?

Authors:  Mohamed Farag
Journal:  J Clin Diagn Res       Date:  2015-01-01

5.  Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH).

Authors:  Nikolaus Becker; Joan Fortuny; Tomas Alvaro; Alexandra Nieters; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Paolo Boffetta; Pier Luigi Cocco; Silvia de Sanjose
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-11       Impact factor: 4.553

6.  The influence of Cox-2 and bioactive lipids on hematological cancers.

Authors:  Sesquile Ramon; Collynn F Woeller; Richard P Phipps
Journal:  Curr Angiogenes       Date:  2013-09-01

Review 7.  Frontline therapy of AML: should the older patient be treated differently?

Authors:  James M Foran
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

8.  Analgesic use during pregnancy and risk of infant leukaemia: a Children's Oncology Group study.

Authors:  S Ognjanovic; C Blair; L G Spector; L L Robison; M Roesler; J A Ross
Journal:  Br J Cancer       Date:  2010-12-14       Impact factor: 7.640

Review 9.  Use of acetaminophen in relation to the occurrence of cancer: a review of epidemiologic studies.

Authors:  Noel S Weiss
Journal:  Cancer Causes Control       Date:  2016-11-10       Impact factor: 2.506

10.  Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

Authors:  Yan Qiao; Tingting Yang; Yong Gan; Wenzhen Li; Chao Wang; Yanhong Gong; Zuxun Lu
Journal:  BMC Cancer       Date:  2018-03-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.